. Endobronchial valves were inserted into the target lobe which was most hyperinflated and least perfused, and had no collateral ventilation with other lobes. Six patients showed clinical improvement after 1 month. Of them, 2 patients improved to dyspnea scale 1 and 4 patients did to scale 2 (P = 0.026). The median FEV1 increased from 0.59 to 0.89 L (51%; P = 0.028) and the median 6MWD increased from 195 to 252 m (29.2%; P = 0.028). Two patients developed a pneumothorax (one requiring drainage) and one patient experienced slight hemoptysis; however, there were no other serious adverse events. BLVR is effective in Asian advanced emphysema patients, with noted clinical improvements in lung function and exercise capacity.
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is character ized by a persistent airflow limitation, which is caused by a mix ture of small airways disease (obstructive bronchiolitis) and pa renchymal destruction (emphysema) (1) . The current therapeu tic options for COPD are smoking cessation and pharmacologic and nonpharmacologic therapies. Pharmacologic therapies include bronchodilators and corticosteroids, which aim to de crease airway resistance and airway inflammation. However, these treatments show limited effectiveness against the decreas ed elastic recoil and hyperinflation associated with emphysema (2) .
Lung volume reduction surgery (LVRS) is a surgical proce dure in which selected areas of the hyperinflated lungs are re sected, making respiratory muscles more effective pressure gen erators and increasing the elastic recoil pressure of the lungs (3, 4) . LVRS has been proposed as a palliative treatment for patients with severe emphysema and was shown to improve lung func tion, exercise tolerance and quality of life in a subgroup of pa tients with upper lobedominant emphysema when compared to medical therapy alone (5) . However, the substantial periop erative morbidity and mortality associated with LVRS has led to the development of lower risk and less invasive bronchoscopic techniques that have similar physiologic mechanisms to LVRS. Among them, endobronchial valves (EBVs) are the most widely used devices for bronchoscopic lung volume reduction (BLVR) and have shown promising results. EBVs are bronchial devices that incorporate a oneway valve that blocks the bronchial lu men leading to a targeted region of the emphysematous lung. EBVs have shown acceptable safety and efficacy when used as a unilateral treatment to improve lung function, exercise toler ance, and quality of life in patients with advanced emphysema (68). EBVs have been granted European Community (Com munauté Européenne [CE] ) mark approval for use in BLVR and many patients worldwide have benefited from the procedure.
However, the use of EBVs in BLVR in Asian emphysema patients has been minimal.
In Korea, EBVs were first introduced and approved for BLVR by the Korean FDA in November 2011, with the first case per formed in July 2012. The aim of this paper was to report the ex perience of the first Asian cases of EBV deployment in advanced emphysema patients treated with BLVR.
MATERIALS AND METHODS

Patients
Patients with advanced emphysema who did not respond to standard treatment for COPD were eligible to undergo BLVR. The inclusion and exclusion criteria are listed in Table 1 . We re cruited subjects which corresponded with such criteria at out patient or inpatient pulmonary clinic. Between July 2012 and March 2013, consecutive seven patients underwent BLVR at Asan Medical Center, Seoul, Korea. They each had a smoking history of more than 10 packyears. Dyspnea was persistent de spite pharmacologic treatment and pulmonary rehabilitation for more than 3 months. Written informed consent was obtain ed from each patient before the procedure. All patients received optimal medical treatment at the time of inclusion and no chan ges were made to their medication regimen after the procedure.
The preoperative evaluation included a physical examina tion, spirometry, chest radiography, lung perfusion computed tomography (CT) scan, and transthoracic echocardiography, as well as measurements of lung volumes by body plethysmogra phy, diffusing capacity for carbon monoxide (DLCO), and exer cise capacity using the 6min walk distance (6MWD) test. The degree of dyspnea was measured using the modified British Medical Research Council (mMRC) questionnaire. Quality of life was assessed by the St. George Respiratory Questionnaire (SGRQ) and COPD Assessment Test (CAT) (9, 10) .
Computed tomography
CT scanning with intravenous contrast medium was performed using a dualsource CT system (SOMATOM Definition; Siemens Healthcare, Forchiheim, Germany) in the dualenergy mode (80 and 140 kV). The perfusion to volume ratio of each lobe was calculated by measuring the iodine to voxel ratio with inhouse software. The detailed CT protocol was described in other pa per (11) . The most hyperinflated and least perfused lobe of the emphysematous lung was selected as the target lobe for BLVR. Additionally, fissure integrity of the target lobe was assessed by a thoracic radiologist. Only patients having complete fissure of the target lobe were selected as subjects (Table 1) .
Procedure
Using flexible bronchoscopy, BLVR was performed by placing oneway EBVs in the bronchi supplying the most hyperinflated parts of the emphysematous lungs. Patients were administered inhaled salbutamol and intravenous anesthesia with midazol am before BLVR. The Zephyr ® EBV (Pulmonx Inc., Redwood City, CA, USA) was used in all patients in this study. It is a self expanding nitinol (nickeltitanium) stent with a silicone one way duckbill valve that allows release of gas and mucus during exhalation but blocks entry of air during inhalation. It is avail able in two sizes (4.07.0 mm and 5.58.5 mm) to fit the subseg mental, segmental, and lobar bronchi. These EBVs can be re moved or repositioned with bronchoscopy. Before the proce dure, the Chartis ® System (Pulmonx Inc.) was used to confirm that the target lobe had no collateral ventilation with the non target lobe. The Chartis ® system is an endobronchial catheter based device for estimating collateral resistance, which assists in the selection of suitable patients for lung volume reduction (12, 13) . When the Chartis ® system did not give reliable results in target lobe, adjacent lobe was tested instead. If adjacent lobe had no collateral ventilation on the Chartis ® system, target lobe was considered to have no collateral ventilation.
The EBV was delivered to the target bronchi using a flexible delivery catheter (with the valve in situ), which was inserted through the working channel of a standard bronchoscope. Valves were places unilaterally in either the lobar, segmental, or sub segmental bronchi in the targeted lobe. The physician deter mined the number of valves that were required to occlude the target lobe completely. Chest radiographs were taken within 1 hr of the procedure and on the following day to assess atelecta sis of the target lobe, diaphragm shift, and pneumothorax.
Follow-up and outcome measures
Followup evaluations were performed at 1 month postproce dure. Patients were reevaluated with chest radiograph, pulmo nary function test, exercise tolerance as measured with the 6 M WD test, a quality of life assessment, and any adverse events were noted. Clinical efficacy measures included forced expira tory volume in 1 second (FEV1), the 6MWD test, and the mMRC dyspnea scale.
Statistical analysis
Descriptive statistics were expressed as median and range be cause of the limited number of patients. The Wilcoxon signed rank test was used to assess the significance of differences be tween variables at baseline and at followup. A value of P < 0.05 was considered to indicate statistical significance. Statistical anal yses were performed using SPSS, version 19.0 for Windows (SPSS, Chicago, IL, USA).
Ethics statement
This study was approved by the Asan Medical Center institu tional review board (Approval No. 20130368 and 20140194). Written informed consent was obtained from all patients.
RESULTS
The demographic and baseline characteristics of all patients are summarized in Table 2 . They were aged between 53 and 69 yr and had severe dyspnea, poor lung function and low exercise capacity (mMRC dyspnea scale 34; median FEV1, 0.59 L, 19.0% predicted; median 6MWD, 195 m). All patients had severe hy perinflated emphysema with a median residual volume (RV) of 193% predicted. Patient No. 1 underwent BLVR because of per sistent air leakage through a chest tube after spontaneous pneu mothorax. Surgical bleb resection was considered too danger ous because he had poor lung function.
Endobronchial valve treatment
Most patients had upper lobe predominant emphysema and the right upper lobe was used as the target lobe in all patients except for patient No. 6. The treating physician inserted two to four small or large valves into the bronchi of the target lobe de pending on the anatomical variation of the bronchi. The target lobe of each patient, as well as the procedural details, is shown in Table 3 .
Treatment efficacy
Subsegmental linear atelectasis of the target lobe and expan sion of other lobes were observed shortly after BLVR in most patients. The clinical efficacy of the procedure at 1 month post procedure is shown in Table 4 and Fig. 1 . Among seven patients, six patients showed clinical improvement with no clinical im provement seen in patient No 4.
The median FEV1 significantly increased from 0.59 L to 0.89 L (51%; P = 0.028). Other pulmonary functional variables such as forced vital capacity (FVC), RV, and total lung capacity (TLC) also showed improvement although the changes were not sta tistically significant. Decreases in RV and TLC were noted to parallel increases in FEV1 and FVC. Overall, dyspnea was mark edly improved after the procedure (P = 0.026): two patients im 
DISCUSSION
BLVR with EBV showed efficacy in Asian emphysema patients with noted improvements in pulmonary function, quality of life, and exercise capacity. The clinical efficacy rate was 85.7% (six of seven patients). Safety was also demonstrated with an absence of serious adverse events, although longterm follow up is needed to confirm safety over the long term. To our knowl edge, this is the first report on the use of Zephyr ® EBV in BLVR in Asia.
Asian patients with COPD may have characteristics that pre dispose them to different BLVR outcomes than Western patients. Although tobacco smoking is the major cause of COPD, previ ous exposure to biomass fuels or dusty jobs, and treated pulmo nary tuberculosis are other notable causes of COPD in Asia (14, 15) . Especially, the prevalence of pulmonary tuberculosis is as high as 70 in 100,000 in Korea, and previous pulmonary tuber culosis is an important risk factor for Korean patients with COPD (16) . Indeed, two of seven patients (Patients No. 5 and No. 7) had past history of pulmonary tuberculosis in our study. Patient No. 5 had focal area of parenchymal distortion in right upper lobe and patient No. 7 had focal fibrosis with linear atelectasis in both upper lobes. However, they did not have any cavitary le sions. Prior pulmonary tuberculosis history did not affect effi cacy or adverse events such as pneumothorax. In addition, ge netic diseases such as alpha1 antitrypsin deficiency, which can generate panlobular emphysema, are extremely scarce in Korea. Nonetheless, our results were consistent with those of Western countries.
COPD is thought to be a heterogeneous disease, which has various distinct clinical outcomes despite similarities in airflow limitations (FEV1) (1719) . A particular COPD phenotype may be related to a distinct natural history and may respond differ ently to treatment than another phenotype. Identification and targeted treatment of specific phenotypes within the broad spec trum of COPD is important to improve overall treatment out comes for the disease (20) . Emphysema is one representative phenotype of COPD with a distinct pathophysiologic mecha nism. However, therapeutic approaches have had limited effec tiveness due to a decrease in lung elastic recoil, air entrapment, and hyperinflation associated with emphysema. Although lung volume reduction surgery is a proven palliative procedure for emphysema, the very high operative mortality has limited its use (5) .
Several nonsurgical lung volume reduction techniques have been developed, including unidirectional valves (EBV and in trabronchial valve) deployment, lung volume reduction coils, biologic lung volume reduction, thermal vapor ablation, and airway tract bypass (21, 22) . Among them, EBV deployment has the most abundant clinical data showing its feasibility and safe ty. EBV clinical trials demonstrated improvement in lung func tion (FEV1), exercise tolerance (6MWD), and symptoms in pa tients with advanced heterogeneous emphysema (7, 8) . Our study showed better clinical efficacy rate with other clinical tri als (7) . This is likely due to the appropriate selection of patients and the target lobe in the present study. The right upper lobe was selected preferentially as the target lobe, which may be as sociated with larger lung volume reductions. Furthermore, we confirmed that the target lobe had no collateral ventilation. Suc cessful BLVR with EBV is dependent on the emphysema distri bution and degree of collateral ventilation (6, 23) . Complete lo bar occlusion by valve insertion provides an effective therapy for patients with severe heterogeneous upper lobe or lower lobe predominant emphysema and little collateral ventilation of em physema. The use of CT scan is important in selecting patients with heterogeneous emphysema and for identifying fissure in tegrity. Unlike other studies, we performed preprocedure dual energy perfusion CT instead of ventilationperfusion scintigra phy in all patients to identify the target lobe (11, 24) , which was defined as the most hyperinflated and least perfused lobe in our study. In addition to dualenergy perfusion CT, we perform ed a balloon occlusion test (Chartis ® Pulmonary Assessment System) to confirm that the target lobe had no collateral venti lation prior to insertion of the valve. Judicious patient selection using perfusion CT scan and a balloon occlusion test may have led to the excellent outcomes seen in our study.
The exact mechanism by which EBV deployment improves Furthermore, quantitative assessment with ventilationperfu sion CT scan using xenon before and after procedure may shed further light on the mechanism by which BLVR leads to clinical improvement in emphysema symptoms (25) . Although we noted a high clinical efficacy rate in our study, one patient (No. 4) showed no benefit. We verified that his tar get lobe had no collateral ventilation on the Chartis ® system. However, there was no volume reduction noted on the postpro cedure chest radiography. We then removed his preexisting valves, which had been inserted in his right upper lobe, and placed further valves into his left upper lobe after confirming that the new target lobe was completely fissured and that there was no collateral ventilation using a balloon occlusion test. How ever, this reinsertion also did not lead to lung volume reduc tion. These findings suggest there may be very small channel between the lobes, such as the channel of Lambert (26) , which cannot be detected by a balloon occlusion test.
BLVR is associated with several complications including pneu mothorax, hemoptysis, pneumonia, and acute exacerbation of COPD (7), of which pneumothorax is the most common. In our study, the rate of pneumothorax (28.6%) was too high compared to VENT trial (4.2%) (7) . This difference was due to exclusion of patients with collateral ventilation of the target lobe using CT scan and the Chartis ® system. Inducing complete atelectasis of target lobe using such pretests to increase clinical efficacy would generate more pneumothorax. In our study, one patient (pa tient No. 3) experienced pneumothorax requiring tube thora cotomy. His clinical outcomes were relatively poorer than those observed in the other patients (ΔFEV1% change, 16.1%; ΔmMRC dyspnea scale, 1; Δ6MWD% change, 25.0%). It is thought that pneumothorax develops when the target lobe collapses and the adjacent lobe inflates abruptly after complete occlusion of the target lobe. There have been no studies on factors that may be predictive of pneumothorax, or measures that may be taken to prevent it. Such studies are warranted to avoid or minimize this complication.
There are some limitations in this study. First, small numbers of subjects were monitored in a short period of time. Some data of patient No. 1 were not available. Additionally, follow up of CT scan was not performed. Longterm followup data including changes in quantitative CT measures for more patients would be helpful in determining of clinical efficacy.
BLVR is effective in Asian patients with advanced heteroge neous emphysema, showing noted clinical improvements in lung function and exercise capacity. Judicious patient selection may be important to increase the efficacy and safety of BLVR, regardless of patient ethnicity. We recommend that BLVR with EBV to be considered in other Asian countries.
